Company

Fujian Shengdi Pharmaceutical Co.

3 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

SEP 8, 2026 · PHASE 1 TRIAL

A Single-Dose Pharmacokinetic Study of HRS-4729 Injection in Healthy Participants and Patients With Renal Impairment

ClinicalTrials.gov

Phase 1 single-dose pharmacokinetic study in a small, planned cohort with no results yet posted; registry record only describes the protocol.

PreliminaryNCT07807059 Metabolic Dysfunction Associated Steatotic Liver Disease/steatohepatitis (MASLD/HRS-4729

Reported

Planned sample size32

Allocation: healthy participants8

Allocation: mild renal impairment8

AUG 13, 2026 · PHASE 3 TRIAL

A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects

ClinicalTrials.gov

This is a registry record of a Phase 3 RCT currently recruiting, with no posted results; the study design is sound but evidence cannot be assessed until outcomes are reported.

PreliminaryHRS9531 Tablet HRS9531 Tablet Placebo NCT07670884

Reported

PhasePHASE 3

Planned enrollment675

Treatment duration52 weeks

JUL 31, 2026 · PHASE 1 TRIAL

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS9531 Injection in Adolescents With Obesity

ClinicalTrials.gov

Phase 1 trial in recruitment with no results posted; establishes only planned design and safety endpoints in adolescents with obesity.

PreliminaryHRS9531 injection；Placebo NCT07559136 Overweight and Obesity

Reported

Planned enrollment48

PhasePhase 1

Primary outcome measureAdverse Events (AEs), up to Week 28